Amwell price target lowered to $10.50 from $20 at Morgan Stanley

Morgan Stanley analyst Craig Hettenbach lowered the firm’s price target on Amwell (AMWL) to $10.50 from $20 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group. Among Healthcare Technology and Providers, the firm remains selective due to mixed demand and policy uncertainties, the analyst added.